本文選題：甲氧氯普胺 + 阿瑞匹坦�。� 參考：《廣東醫(yī)學(xué)》2017年09期

【摘要】：目的比較甲氧氯普胺(MPD)與阿瑞匹坦(APD)在聯(lián)合地塞米松基礎(chǔ)上預(yù)防高致吐性化療(HEC)引起的延遲性惡心嘔吐的有效性和安全性。方法將接受HEC的實體瘤患者隨機分為MPD組(30例)和APD組(31例),MPD組的止吐方案為MPD 20 mg,2次/d(d2~4);帕洛諾司瓊0.25 mg(d1);地塞米松20 mg(d1),8 mg,2次/d(d2~4)。APD組的止吐方案為APD 125 mg(d1),80 mg(d2~3);帕洛諾司瓊0.25 mg(d1);地塞米松12 mg(d1),8 mg(d2~4)。主要研究終點是延遲期(化療后24~120 h)內(nèi)獲得完全緩解(定義為無嘔吐及未使用解救性止吐藥物)的患者百分比(CRR),次要研究終點是不良反應(yīng)發(fā)生率。結(jié)果 MPD組與APD組在延遲期惡心嘔吐的CRR分別為83.3%(25/30)和80.6%(25/31),差異無統(tǒng)計學(xué)意義(P0.05)。兩組主要不良反應(yīng)為便秘、乏力及呃逆,不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(P0.05),患者均可以耐受。結(jié)論 MPD聯(lián)合帕洛諾司瓊、地塞米松的止吐方案與標(biāo)準(zhǔn)的三聯(lián)止吐方案(APD、帕洛諾司瓊及地塞米松)相比,在HEC中具有相似的療效及安全性。
[Abstract]:Objective to compare the efficacy and safety of metoclopramide (MPD) and aripitan (APD) combined with dexamethasone in the prevention of delayed nausea and vomiting induced by hyperemetic chemotherapy. Methods Thirty patients with solid tumor receiving HEC were randomly divided into MPD group (n = 30) and APD group (n = 31). The antiemetic regimen in the APD group was as follows: MPD 20 mg / d 2 / d 2X; paronosetron 0.25 mg / d 1; dexamethasone 20 mg / d 1 / 8 mg / L / 2 / d 2 / d 4. APD group: APD 125 mg / d ~ (1 / d) 80 mg / d ~ (2) D ~ (2); Qiong 0.25 mg / d ~ (-1); dexamethasone 12 mg / d ~ (-1) ~ (8 mg / d ~ (2) ~ (4). The main end point of the study was the percentage of patients with complete remission (defined as no vomiting and no use of rescue antiemetic drugs) during the delayed period (24 to 120 hours after chemotherapy), and the secondary endpoint was the incidence of adverse reactions. Results the CRR of MPD group and APD group in delayed nausea and vomiting were 83.3 / 30 and 80.625 / 31, respectively. There was no significant difference between them (P 0.05). The main adverse reactions of the two groups were constipation, fatigue and hiccup. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion MPD combined with paronosetron and dexamethasone has a similar efficacy and safety in HEC compared with standard triple antiemetic regimen (APD, Palonosetron and dexamethasone).
【作者單位】： 南方醫(yī)科大學(xué)廣州臨床醫(yī)學(xué)院;廣州軍區(qū)廣州總醫(yī)院腫瘤科;
【基金】：國家自然科學(xué)基金資助項目(編號:81172225,81472172)
【分類號】：R730.53

【相似文獻】

相關(guān)期刊論文 前3條

1 畢清;趙明利;任宏軒;田青;鮑明亮;;鹽酸帕洛諾司瓊預(yù)防化療致延遲性惡心、嘔吐的臨床觀察[J];實用臨床醫(yī)藥雜志;2010年17期

2 裴俊文;孫太振;楊峰;付檳梵;;止瀉解毒湯預(yù)防伊立替康所致延遲性腹瀉的臨床研究[J];中醫(yī)學(xué)報;2013年05期

3 ;[J];;年期

相關(guān)會議論文 前1條

1 王盈;林英城;;遲發(fā)性化療相關(guān)惡心嘔吐的治療進展[A];中國腫瘤內(nèi)科進展 中國腫瘤醫(yī)師教育（2014）[C];2014年

，

本文編號：1921934